ORIC Stock Discussion
Oric Pharmaceuticals, Inc. Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Recent Comments
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
From the Blog
Featured Articles